Abbonarsi

Decrease in GPSM2 mediated by the natural product luteolin contributes to colon adenocarcinoma treatment and increases the sensitivity to fluorouracil - 16/06/24

Doi : 10.1016/j.biopha.2024.116847 
Chunjiao Yang a, b, 1, Lina Wu c, d, 1, Xin Jin e, 1, Aoran Liu a, Zhitao Jing f, Chuhan Feng g, Zhengting Guo h, Yuzhe Zhang a, Yanju Ma i, Fang Li a, Zhenpeng Wen a, j, Lirong Yan a, Yi Yang k, Xu Ji f, , Ye Zhang a,
a The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China 
b Department of Oncology, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, Guangxi, China 
c Department of Laboratory Medicine, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, Liaoning 110004, China 
d Liaoning Clinical Research Center for Laboratory Medicine, Shenyang, China 
e Department of Respiratory Medicine, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, Guangxi, China 
f The First Hospital of China Medical University, Shenyang, China 
g Liaoning University Of Traditional Chinese Medicine, Shenyang, China 
h The First Clinical College, China Medical University, Shenyang, China 
i Department of Medical Oncology, Cancer Hospital of China Medical University, China 
j Cancer Center, West China Hospital, Sichuan University, Chengdu, China 
k Department of Laboratory Animal Science, China Medical University, Shenyang, China 

Corresponding authors.

Abstract

Luteolin, a monomeric substance, is a natural product of the Brucea javanica (BJ) plant. Brucea javanica oil emulsion injection (BJOEI) is a proprietary Chinese medicine purified from BJ that is widely used clinically as an anti-tumor treatment. Although a growing body of research suggests that luteolin and BJOEI have anti-tumor effects, the molecular mechanism of action has not been fully elucidated. In this study, through molecular docking technology, we found that luteolin can interact directly with GPSM2 and regulate the FoxO signaling pathway through GPSM2 . In addition, the inhibitory effect of luteolin on colon adenocarcinoma (COAD) cells was found to be offset by knockdown of GPSM2 . In contrast, the anti-proliferative effects of luteolin could be notably reversed by overexpression of GPSM2 . The results reveal that GPSM2 is crucial in luteolin-mediated anti-proliferative effects. The mediation of anti-proliferative effects by GPSM2 has also been indirectly demonstrated in RKO and SW480 xenograft mice models. In addition, we verified that BJOEI inhibits the progression of COAD by mediating GPSM2 and regulating the FoxO signaling pathway. We also found that BJOEI achieved a better anti-tumor effect when combined with fluorouracil injection. Collectively, our data show that the anti-tumor effects of BJOEI and luteolin on COAD are GPSM2 -dependent and downregulating the expression of GPSM2 to regulate the FoxO signaling pathway may be an effective way to treat COAD.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




Il testo completo di questo articolo è disponibile in PDF.

Highlights

Luteolin is a natural product of the Brucea javanica monomeric component that is widely used in antitumour treatment.
Luteolin and Brucea javanica oil emulsion injection can inhibit colon cancer progression.
The anticancer mechanism of luteolinrevealed and laid a solid foundation for its clinical application.

Il testo completo di questo articolo è disponibile in PDF.

Keywords :  G-protein-signal modulator 2 ( GPSM2 ) , Colon adenocarcinoma (COAD), Luteolin, Brucea javanica oil emulsion injection (BJOEI) , FoxO signaling pathway


Mappa


© 2024  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 176

Articolo 116847- luglio 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Membrane-targeting, ultrashort lipopeptide acts as an antibiotic adjuvant and sensitizes MDR gram-negative pathogens toward narrow-spectrum antibiotics
  • Apurva Panjla, Grace Kaul, Manjulika Shukla, Abdul Akhir, Sarita Tripathi, Ashish Arora, Sidharth Chopra, Sandeep Verma
| Articolo seguente Articolo seguente
  • Pro-cognitive effects of dual tacrine derivatives acting as cholinesterase inhibitors and NMDA receptor antagonists
  • Marketa Chvojkova, David Kolar, Katarina Kovacova, Lada Cejkova, Anna Misiachna, Kristina Hakenova, Lukas Gorecki, Martin Horak, Jan Korabecny, Ondrej Soukup, Karel Vales

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.